Ligand specificity in fragment-based drug design

Journal of Medicinal Chemistry

Volumn 53, Issue 14, 2010, Pages 5256-5266

  Barelier, Sarah ^a   Pons, Julien ^a   Gehring, Kalle ^b   Lancelin, Jean Marc ^a   Krimm, Isabelle ^a  

^a Institut des Sciences Analytiques   (France)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN SERUM ALBUMIN; PEROXIREDOXIN 5; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN INHIBITOR; PROTEIN MCL 1;

ARTICLE; DRUG BINDING; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG SPECIFICITY; DRUG STRUCTURE; HUMAN; MACROMOLECULE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

DRUG DESIGN; HUMANS; HYDROPHOBICITY; LIGANDS; MAGNETIC RESONANCE SPECTROSCOPY; PEROXIREDOXINS; PHARMACEUTICAL PREPARATIONS; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-BCL-2; SERUM ALBUMIN; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77954724107     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm100496j     Document Type: Article

References (63)

1. Hajduk, P. J.; Greer, J. A decade of fragment-based drug design: strategic advances and lessons learned Nat. Rev. Drug Discovery 2007, 6, 211-219
2. Congreve, M.; Chessari, G.; Tisi, D.; Woodhead, A. J. Recent developments in fragment-based drug discovery J. Med. Chem. 2008, 51, 3661-3680
3. Shuker, S. B.; Hajduk, P. J.; Meadows, R. P.; Fesik, S. W. Discovering high-affinity ligands for proteins: SAR by NMR Science 1996, 274, 1531-1534
4. Zartler, E. D.; Shapiro, M. J., Eds. Fragment-Based Drug Discovery: A Practical Approach; John Wiley & Sons, Ltd.: Chichester, U.K., 2008; p 296.
5. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection Drug Discovery Today 2004, 9, 430-431
6. Fink, T.; Bruggesser, H.; Reymond, J. L. Virtual exploration of the small-molecule chemical universe below 160 Da Angew. Chem., Int. Ed. 2005, 44, 1504-1508
7. Bohacek, R. S.; McMartin, C.; Guida, W. C. The art and practice of structure-based drug design: a molecular modeling perspective Med. Res. Rev. 1996, 16, 3-50
8. Hann, M. M.; Leach, A. R.; Harper, G. Molecular complexity and its impact on the probability of finding leads for drug discovery J. Chem. Inf. Comput. Sci. 2001, 41, 856-864
9. Oprea, T. I.; Davis, A. M.; Teague, S. J.; Leeson, P. D. Is there a difference between leads and drugs? A historical perspective J. Chem. Inf. Comput. Sci. 2001, 41, 1308-1315
10. Teague, S. J.; Davis, A. M.; Leeson, P. D.; Oprea, T. The design of leadlike combinatorial libraries Angew. Chem., Int. Ed. 1999, 38, 3743-3748
11. Howard, N.; Abell, C.; Blakemore, W.; Chessari, G.; Congreve, M.; Howard, S.; Jhoti, H.; Murray, C. W.; Seavers, L. C.; van Montfort, R. L. Application of fragment screening and fragment linking to the discovery of novel thrombin inhibitors J. Med. Chem. 2006, 49, 1346-1355
12. Hajduk, P. J.; Gomtsyan, A.; Didomenico, S.; Cowart, M.; Bayburt, E. K.; Solomon, L.; Severin, J.; Smith, R.; Walter, K.; Holzman, T. F.; Stewart, A.; McGaraughty, S.; Jarvis, M. F.; Kowaluk, E. A.; Fesik, S. W. Design of adenosine kinase inhibitors from the NMR-based screening of fragments J. Med. Chem. 2000, 43, 4781-4786
13. Fahr, B. T.; O'Brien, T.; Pham, P.; Waal, N. D.; Baskaran, S.; Raimundo, B. C.; Lam, J. W.; Sopko, M. M.; Purkey, H. E.; Romanowski, M. J. Tethering identifies fragment that yields potent inhibitors of human caspase-1 Bioorg. Med. Chem. Lett. 2006, 16, 559-562
14. Petros, A. M.; Dinges, J.; Augeri, D. J.; Baumeister, S. A.; Betebenner, D. A.; Bures, M. G.; Elmore, S. W.; Hajduk, P. J.; Joseph, M. K.; Landis, S. K.; Nettesheim, D. G.; Rosenberg, S. H.; Shen, W.; Thomas, S.; Wang, X.; Zanze, I.; Zhang, H.; Fesik, S. W. Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis J. Med. Chem. 2006, 49, 656-663
15. Edwards, P. D.; Albert, J. S.; Sylvester, M.; Aharony, D.; Andisik, D.; Callaghan, O.; Campbell, J. B.; Carr, R. A.; Chessari, G.; Congreve, M.; Frederickson, M.; Folmer, R. H.; Geschwindner, S.; Koether, G.; Kolmodin, K.; Krumrine, J.; Mauger, R. C.; Murray, C. W.; Olsson, L. L.; Patel, S.; Spear, N.; Tian, G. Application of fragment-based lead generation to the discovery of novel, cyclic amidine beta-secretase inhibitors with nanomolar potency, cellular activity, and high ligand efficiency J. Med. Chem. 2007, 50, 5912-5925
16. Soellner, M. B.; Rawls, K. A.; Grundner, C.; Alber, T.; Ellman, J. A. Fragment-based substrate activity screening method for the identification of potent inhibitors of the Mycobacterium tuberculosis phosphatase PtpB J. Am. Chem. Soc. 2007, 129, 9613-9615
17. Frederickson, M.; Callaghan, O.; Chessari, G.; Congreve, M.; Cowan, S. R.; Matthews, J. E.; McMenamin, R.; Smith, D. M.; Vinkovic, M.; Wallis, N. G. Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator J. Med. Chem. 2008, 51, 183-186
18. Proschak, E.; Sander, K.; Zettl, H.; Tanrikulu, Y.; Rau, O.; Schneider, P.; Schubert-Zsilavecz, M.; Stark, H.; Schneider, G. From molecular shape to potent bioactive agents II: fragment-based de novo design ChemMedChem 2009, 4, 45-48
19. Jahnke, W.; Erlanson, D. A., Eds. Fragment-Based Approaches in Drug Discovery; Methods and Principles in Medicinal Chemistry, Vol. 34; Wiley-VCH Verlag: Weinheim, Germany, 2006; p 369.
20. Hajduk, P. J.; Bures, M.; Praestgaard, J.; Fesik, S. W. Privileged molecules for protein binding identified from NMR-based screening J. Med. Chem. 2000, 43, 3443-3447
21. Chen, Y.; Shoichet, B. K. Molecular docking and ligand specificity in fragment-based inhibitor discovery Nat. Chem. Biol. 2009, 5, 358-364
22. Chen, I. J.; Hubbard, R. E. Lessons for fragment library design: analysis of output from multiple screening campaigns. J. Comput.-Aided Mol. Des. [Online early access]. Published Online: June 3, 2009.
23. Adams, J. M.; Cory, S. The Bcl-2 protein family: arbiters of cell survival Science 1998, 281, 1322-1326
24. Petros, A. M.; Olejniczak, E. T.; Fesik, S. W. Structural biology of the Bcl-2 family of proteins Biochim. Biophys. Acta 2004, 1644, 83-94
25. Cory, S.; Huang, D. C.; Adams, J. M. The Bcl-2 family: roles in cell survival and oncogenesis Oncogene 2003, 22, 8590-8607
26. Sattler, M.; Liang, H.; Nettesheim, D.; Meadows, R. P.; Harlan, J. E.; Eberstadt, M.; Yoon, H. S.; Shuker, S. B.; Chang, B. S.; Minn, A. J.; Thompson, C. B.; Fesik, S. W. Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis Science 1997, 275, 983-986
27. Adams, J. M.; Cory, S. The Bcl-2 apoptotic switch in cancer development and therapy Oncogene 2007, 26, 1324-1337
28. Lugovskoy, A. A.; Degterev, A. I.; Fahmy, A. F.; Zhou, P.; Gross, J. D.; Yuan, J.; Wagner, G. A novel approach for characterizing protein ligand complexes: molecular basis for specificity of small-molecule Bcl-2 inhibitors J. Am. Chem. Soc. 2002, 124, 1234-1240
29. Mohammad, R. M.; Goustin, A. S.; Aboukameel, A.; Chen, B.; Banerjee, S.; Wang, G.; Nikolovska-Coleska, Z.; Wang, S.; Al-Katib, A. Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1 Clin. Cancer Res. 2007, 13, 2226-2235
30. Nguyen, M.; Marcellus, R. C.; Roulston, A.; Watson, M.; Serfass, L.; Murthy Madiraju, S. R.; Goulet, D.; Viallet, J.; Belec, L.; Billot, X.; Acoca, S.; Purisima, E.; Wiegmans, A.; Cluse, L.; Johnstone, R. W.; Beauparlant, P.; Shore, G. C. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 19512-19517
31. Oltersdorf, T.; Elmore, S. W.; Shoemaker, A. R.; Armstrong, R. C.; Augeri, D. J.; Belli, B. A.; Bruncko, M.; Deckwerth, T. L.; Dinges, J.; Hajduk, P. J.; Joseph, M. K.; Kitada, S.; Korsmeyer, S. J.; Kunzer, A. R.; Letai, A.; Li, C.; Mitten, M. J.; Nettesheim, D. G.; Ng, S.; Nimmer, P. M.; O'Connor, J. M.; Oleksijew, A.; Petros, A. M.; Reed, J. C.; Shen, W.; Tahir, S. K.; Thompson, C. B.; Tomaselli, K. J.; Wang, B.; Wendt, M. D.; Zhang, H.; Fesik, S. W.; Rosenberg, S. H. An inhibitor of Bcl-2 family proteins induces regression of solid tumours Nature 2005, 435, 677-681
32. Prakesch, M.; Denisov, A. Y.; Naim, M.; Gehring, K.; Arya, P. The discovery of small molecule chemical probes of Bcl-x(L) and Mcl-1 Bioorg. Med. Chem. 2008, 16, 7443-7449
33. Qiu, J.; Levin, L. R.; Buck, J.; Reidenberg, M. M. Different pathways of cell killing by gossypol enantiomers Exp. Biol. Med. (Maywood, NJ, U. S.) 2002, 227, 398-401
34. Rega, M. F.; Leone, M.; Jung, D.; Cotton, N. J.; Stebbins, J. L.; Pellecchia, M. Structure-based discovery of a new class of Bcl-xL antagonists Bioorg. Chem. 2007, 35, 344-353
35. Schwartz, P. S.; Manion, M. K.; Emerson, C. B.; Fry, J. S.; Schulz, C. M.; Sweet, I. R.; Hockenbery, D. M. 2-Methoxy antimycin reveals a unique mechanism for Bcl-x(L) inhibition Mol. Cancer Ther. 2007, 6, 2073-2080
36. Tse, C.; Shoemaker, A. R.; Adickes, J.; Anderson, M. G.; Chen, J.; Jin, S.; Johnson, E. F.; Marsh, K. C.; Mitten, M. J.; Nimmer, P.; Roberts, L.; Tahir, S. K.; Xiao, Y.; Yang, X.; Zhang, H.; Fesik, S.; Rosenberg, S. H.; Elmore, S. W. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor Cancer Res. 2008, 68, 3421-3428
37. Knoops, B.; Loumaye, E.; van der Eecken, V. In Peroxiredoxin Systems: Structures and Functions; Flohé, L.; Harris, J. R., Eds.; Subcellular Biochemistry, Vol. 44; Springer: New York, 2007; pp 27 - 40.
38. Karplus, P. A.; Hall, A. In Peroxiredoxin Systems: Structures and Functions; Flohé, L.; Harris, J. R., Eds.; Subcellular Biochemistry, Vol. 44; Springer: New York, 2007; pp 41 - 60.
39. Declercq, J. P.; Evrard, C.; Clippe, A.; Vander Stricht, D.; Bernard, A.; Knoops, B. Crystal structure of human peroxiredoxin 5, a novel type of mammalian peroxiredoxin at 1.5 angstrom resolution J. Mol. Biol. 2001, 311, 751-759
40. Barelier, S.; Linard, D.; Pons, J.; Clippe, A.; Knoops, B.; Lancelin, J. M.; Krimm, I. Discovery of fragment molecules that bind the human peroxiredoxin 5 active site PLoS One 2010, 5, e9744
41. He, X. M.; Carter, D. C. Atomic structure and chemistry of human serum albumin Nature 1992, 358, 209-215
42. Mayer, M.; Meyer, B. Characterization of ligand binding by saturation transfer difference NMR spectroscopy Angew. Chem., Int. Ed. 1999, 38, 1784-1788
43. Dalvit, C.; Pevarello, P.; Tato, M.; Veronesi, M.; Vulpetti, A.; Sundstrom, M. Identification of compounds with binding affinity to proteins via magnetization transfer from bulk water J. Biomol. NMR 2000, 18, 65-68
44. Hajduk, P. J.; Huth, J. R.; Fesik, S. W. Druggability indices for protein targets derived from NMR-based screening data J. Med. Chem. 2005, 48, 2518-2525
45. Congreve, M.; Carr, R.; Murray, C.; Jhoti, H. A "rule of three" for fragment-based lead discovery? Drug Discovery Today 2003, 8, 876-877
46. Fejzo, J.; Lepre, C. A.; Peng, J. W.; Bemis, G. W.; Ajay; Murcko, M. A.; Moore, J. M. The SHAPES strategy: an NMR-based approach for lead generation in drug discovery Chem. Biol. 1999, 6, 755-769
47. Bemis, G. W.; Murcko, M. A. Properties of known drugs. 2. Side chains J. Med. Chem. 1999, 42, 5095-5099
48. Baurin, N.; Aboul-Ela, F.; Barril, X.; Davis, B.; Drysdale, M.; Dymock, B.; Finch, H.; Fromont, C.; Richardson, C.; Simmonite, H.; Hubbard, R. E. Design and characterization of libraries of molecular fragments for use in NMR screening against protein targets J. Chem. Inf. Comput. Sci. 2004, 44, 2157-2166
49. Dalvit, C.; Fogliatto, G.; Stewart, A.; Veronesi, M.; Stockman, B. WaterLOGSY as a method for primary NMR screening: practical aspects and range of applicability J. Biomol. NMR 2001, 21, 349-359
50. Denisov, A. Y.; Madiraju, M. S.; Chen, G.; Khadir, A.; Beauparlant, P.; Attardo, G.; Shore, G. C.; Gehring, K. Solution structure of human Bcl-w: modulation of ligand binding by the C-terminal helix J. Biol. Chem. 2003, 278, 21124-21128
51. Barelier, S.; Pons, J.; Marcillat, O.; Lancelin, J. M.; Krimm, I. Fragment-based deconstruction of Bcl-xL inhibitors J. Med. Chem. 2010, 53, 2577-2588
52. Ghuman, J.; Zunszain, P. A.; Petitpas, I.; Bhattacharya, A. A.; Otagiri, M.; Curry, S. Structural basis of the drug-binding specificity of human serum albumin J. Mol. Biol. 2005, 353, 38-52
53. Varshney, A.; Sen, P.; Ahmad, E.; Rehan, M.; Subbarao, N.; Khan, R. H. Ligand binding strategies of human serum albumin: how can the cargo be utilized? Chirality 2010, 22, 77-87
54. Stockman, B. J.; Dalvit, C. NMR screening techniques in drug discovery and drug design Prog. Nucl. Magn. Reson. Spectrosc. 2002, 41, 187-231
55. Dalvit, C. NMR methods in fragment screening: theory and a comparison with other biophysical techniques Drug Discovery Today 2009, 14, 1051-1057
56. Liu, G.; Botting, C. H.; Evans, K. M.; Walton, J. A.; Xu, G.; Slawin, A. M.; Westwood, N. J. Optimisation of conoidin A, a peroxiredoxin inhibitor ChemMedChem 2010, 5, 41-45
57. van Delft, M. F.; Wei, A. H.; Mason, K. D.; Vandenberg, C. J.; Chen, L.; Czabotar, P. E.; Willis, S. N.; Scott, C. L.; Day, C. L.; Cory, S.; Adams, J. M.; Roberts, A. W.; Huang, D. C. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized Cancer Cell 2006, 10, 389-399
58. Czabotar, P. E.; Lee, E. F.; van Delft, M. F.; Day, C. L.; Smith, B. J.; Huang, D. C.; Fairlie, W. D.; Hinds, M. G.; Colman, P. M. Structural insights into the degradation of Mcl-1 induced by BH3 domains Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 6217-6222
59. Bernardo, P. H.; Sivaraman, T.; Wan, K. F.; Xu, J.; Krishnamoorthy, J.; Song, C. M.; Tian, L.; Chin, J. S.; Lim, D. S.; Mok, H. Y.; Yu, V. C.; Tong, J. C.; Chai, C. L. Structural insights into the design of small molecule inhibitors that selectively antagonize Mcl-1 J. Med. Chem. 2010, 53, 2314-2318
60. Bretonnet, A. S.; Jochum, A.; Walker, O.; Krimm, I.; Goekjian, P.; Marcillat, O.; Lancelin, J. M. NMR screening applied to the fragment-based generation of inhibitors of creatine kinase exploiting a new interaction proximate to the ATP binding site J. Med. Chem. 2007, 50, 1865-1875
61. Dalvit, C.; Fasolini, M.; Flocco, M.; Knapp, S.; Pevarello, P.; Veronesi, M. NMR-based screening with competition water-ligand observed via gradient spectroscopy experiments: detection of high-affinity ligands J. Med. Chem. 2002, 45, 2610-2614
62. Delaglio, F.; Grzesiek, S.; Vuister, G. W.; Zhu, G.; Pfeifer, J.; Bax, A. NMRPipe: a multidimensional spectral processing system based on UNIX pipes J. Biomol. NMR 1995, 6, 277-293
63. Johnson, B. A.; Blevins, R. A. NMR View: a computer-program for the visualization and analysis of NMR data J. Biomol. NMR 1994, 4, 603-614